ArriVent advances ARR-217 to Phase 1b dose testing
Further dose-optimization data are expected in 2027; ARR-217 has advanced into Phase 1b at 5 and 6 mg/kg Q3W.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ArriVent BioPharma, Inc. (AVBP) announced initial Phase 1 data for ARR-217 (MRG007), its CDH17-targeted antibody-drug conjugate for gastrointestinal cancers, at the 2026 ESMO Congress. As of August 5, 2026, 123 patients with heavily pretreated GI malignancies had been treated across six dose levels from 2 mg/kg to 8 mg/kg, including 113 patients with colorectal cancer.
The ongoing study is multicenter and open-label, and is being conducted in the U.S. and China. ArriVent said ARR-217 advanced into Phase 1b dose optimization at 5 and 6 mg/kg Q3W, with further dose-optimization data expected in 2027. Under its collaboration with Lepu Biopharma, ArriVent holds exclusive rights to develop and commercialize ARR-217 worldwide outside Greater China.
8-K Event Classification
Key Figures
Key Terms
antibody-drug conjugate (ADC) medical
pharmacokinetics medical
Q3W medical
glycan-linked, exatecan-based payload technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many patients were treated in AVBP's ARR-217 Phase 1 study?
What does AVBP's ARR-217 Phase 1 study evaluate?
What is ARR-217 made of?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) |
(Commission File Number) | (IRS
Employer Identification No.) |
| (Address of principal executive offices) | (zip code) |
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01 | Regulation FD Disclosure. |
On October 25, 2026, ArriVent BioPharma, Inc. issued a press release announcing initial Phase 1 data for cadherin-17 (CDH17)-targeted antibody-drug conjugate ARR-217 (MRG007), in patients with gastrointestinal cancers at the European Society for Medical Oncology Congress 2026. A copy of the press release is filed as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 7.01.
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 8.01 | Other Events. |
The information set forth in the press release referred to in Item 7.01 above, other than the second paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated October 25, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ARRIVENT BIOPHARMA, INC. | ||
| By: | /s/ Winston Kung | |
| Winston Kung | ||
| Chief Financial Officer and Treasurer | ||
Date: October 26, 2026
Exhibit 99.1
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
| · | 44.8% ORR at 6mg/kg dose in late-line CRC patients |
| · | ARR-217 was generally well-tolerated |
| · | ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program |
NEWTOWN SQUARE, PA, October 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.
"These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy," said Bing Yao, Ph.D., Chief Executive Officer of ArriVent. "We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study. As the first ADC from our pipeline to enter clinical development, ARR-217 represents an important milestone for our ADC pipeline, and we look forward to dose optimization data expected in 2027."
The ongoing multicenter, open-label Phase 1 study (NCT07066657) conducted in the US and China is evaluating the safety, tolerability, efficacy, and pharmacokinetics of ARR-217 in patients with unresectable, locally advanced, or metastatic solid tumors, with an initial clinical development focus in colorectal, pancreatic, and other gastrointestinal (GI) cancers. As of the August 5, 2026 data cutoff, 123 patients with heavily pretreated GI malignancies were treated across 6 dose levels ranging from 2 mg/kg to 8 mg/kg, including 113 patients with Colorectal Cancer (CRC).
Key Highlights for ARR-217 Phase 1 Study Include:
| · | Strong Anti-tumor Activity with ARR-217 at Multiple Dose Levels |
| o | At 6 mg/kg Q3W dose, 44.8% (13/29) objective response rate (ORR) observed in pre-treated CRC patients, including 7 confirmed partial responses, 4 partial responses pending confirmation, and 2 unconfirmed partial responses |
| o | At 6 mg/kg Q3W dose, 93.1% (27/29) disease control rate (DCR) observed |
| o | At doses 4 mg/kg Q3W and higher, 34.2% (25/73) ORR observed in CRC patients, including 15 confirmed partial responses, 5 partial responses pending confirmation and 5 unconfirmed partial responses |
| o | At doses 4 mg/kg Q3W and higher, 91.8% DCR observed |
| o | Majority of the responding patients remained on study treatment as of the August 5, 2026 data cutoff |
| · | Generally, Well Tolerated Safety Profile |
| o | The most common treatment-related adverse events were Grade 1/2 |
| o | Across all doses, 30.1% (37/123) patients experienced Grade 3 or higher treatment-related adverse events, including neutropenia (12.2%) and diarrhea (8.9%) |
| o | At 6.0 mg/kg Q3W dose, Grade 3 or higher TRAE was 20.4% (10/49) including 2.0% diarrhea (1/49) |
| o | No grade 5 TRAE or ILD observed |
Dose Optimization and Next Steps
ARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg Q3W with further dose optimization data expected in 2027.
About ARR-217
ARR-217 (also known as MRG007) is a potentially best-in-class cadherin-17 (CDH17)-targeted antibody-drug conjugate (ADC), utilizing a glycan-linked, exatecan-based payload. CDH17 is a membranous cell adhesion molecule frequently overexpressed in colorectal cancer and several other gastrointestinal cancers, with limited expression in normal intestinal tissue and pancreatic duct, making it an attractive target for ADC therapy. ArriVent obtained exclusive rights to develop and commercialize ARR-217 worldwide outside of Greater China under a collaboration agreement with Lepu Biopharma Co., Ltd. ARR-217 is the lead clinical candidate from ArriVent's growing ADC portfolio.
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding, business strategy and plans; the activity safety and tolerability of ARR-217; the expected timing and future results of the ongoing clinical study of ARR-217, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com